Novavax CEO Says Drugmaker’s Shot Could Be an ‘Ideal’ Booster
By Robert Langreth
Nov. 1, 2021, 4:19 PM
Novavax Inc.’s top executive said the company’s Covid-19 vaccine could be a good booster option for people who have received other shots, as the drugmaker looks to ramp up output and gain approvals around the world.
“Our vaccine is ideal for boosting,” Chief Executive Officer Stanley Erck said in an interview on Monday with Bloomberg Television.
Erck said the Gaithersburg, Maryland-based company has solved manufacturing problems that delayed its vaccine this year and expects to be able to produce 150 million doses a month with partner Serum Institute of India by December.